Related Experiment Video

Updated: Jul 15, 2026

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
06:07

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model

Published on: June 23, 2023

Destabilization of DJ-1 by familial substitution and oxidative modifications: implications for Parkinson's disease

John D Hulleman1, Hamid Mirzaei, Emmanuel Guigard

  • 1Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana 47907, USA.

Biochemistry
|April 25, 2007
PubMed

Insights

Parkinson's disease (PD) involves DJ-1 protein dysfunction. This study shows that specific mutations and over-oxidation destabilize DJ-1, offering a structural basis for PD and suggesting dimer stabilization as a therapeutic strategy.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Molecular Biology

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder linked to oxidative stress and protein aggregation.
  • DJ-1, a protein with antioxidant and chaperone functions, is crucial for mitigating these toxic processes.
  • Oxidation of DJ-1's cysteine 106 residue may function as an oxidative stress sensor, impacting its neuroprotective role.

Purpose of the Study:

  • To investigate the structural and stability impacts of pathogenic DJ-1 mutations (M26I, E64D) and hydrogen peroxide (H2O2)-induced over-oxidation.
  • To elucidate the role of cysteine 106 oxidation in DJ-1 destabilization and dysfunction.
  • To provide a structural foundation for understanding DJ-1's role in familial and sporadic Parkinson's disease.

Main Methods:

  • Recombinant protein expression and purification of wild-type DJ-1 and its mutants (M26I, E64D, C106A).
  • Treatment with hydrogen peroxide (H2O2) to induce over-oxidation.
  • Structural analysis using techniques to assess secondary structure and aggregation propensity.
  • Thermodynamic stability assays to evaluate dimer stability.

Main Results:

  • The M26I mutation and H2O2-induced over-oxidation destabilized DJ-1, reducing secondary structure and promoting aggregation.
  • Wild-type DJ-1 and the E64D mutant maintained stable dimeric structures.
  • The C106A mutant exhibited enhanced thermodynamic stability and resistance to oxidation-induced destabilization compared to wild-type DJ-1.

Conclusions:

  • DJ-1 destabilization, caused by specific mutations like M26I and over-oxidation, contributes to Parkinson's disease pathogenesis.
  • Oxidation of cysteine 106 is a key factor in DJ-1 destabilization.
  • Stabilizing DJ-1 dimers presents a potential therapeutic strategy for both familial and sporadic forms of Parkinson's disease.

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...